抗血栓治疗新靶点——凝血因子Ⅺ

Factor Ⅺ-a promising anticoagulation target

血栓相关性疾病在人群中广泛发生，而其主要治疗药物存在一定比例的出血风险，华法林等药物尚存在需要长期监测凝血功能等不足。是否存在一种抗凝效果好、出血风险小且方便应用的药物是目前研究的重点。临床发现在凝血因子Ⅺ缺乏人群中，其血栓栓塞性疾病发生率低，且多项动物模型实验均提示Ⅺ因子缺乏模型血栓形成比例降低，且出血比例较低，近期临床试验也得到了类似结果，降低Ⅺ因子水平可能成为抗血栓治疗新的重要靶点。

Thromboembolic disorders are widely found nowadays. A certain percentage of bleeding event will occur in available anticoagulation therapies, especially for warfarin, which requires ongoing dose adjustment by means of regular laboratory monitoring to prevent under or over anticoagulation. Is there an approach which could provide antithrombotic protection with reduced bleeding and be convenient is the point of researches. Factor Ⅺ deficiency patients tend to decrease morbidity in thrombotic diseases, moreover, several animal experiments have demonstrated that factor Ⅺ deficiency could reduce thrombotic rate with little effect on hemostasis. Recent clinical studies have confirmed the similar result. Inhibition of factor Ⅺ activity may be a promising antithrombotic target.